[go: up one dir, main page]

CR20180185A - Métodos y composiciones para el tratamiento de estados de enfermedad asociados con respuestas inflamatorias anormales - Google Patents

Métodos y composiciones para el tratamiento de estados de enfermedad asociados con respuestas inflamatorias anormales

Info

Publication number
CR20180185A
CR20180185A CR20180185A CR20180185A CR20180185A CR 20180185 A CR20180185 A CR 20180185A CR 20180185 A CR20180185 A CR 20180185A CR 20180185 A CR20180185 A CR 20180185A CR 20180185 A CR20180185 A CR 20180185A
Authority
CR
Costa Rica
Prior art keywords
methods
compositions
hydrate
crystal
compound
Prior art date
Application number
CR20180185A
Other languages
English (en)
Inventor
Luigi; Franchi
Gary D ; Glick
Original Assignee
First Wave Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by First Wave Bio Inc filed Critical First Wave Bio Inc
Publication of CR20180185A publication Critical patent/CR20180185A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Esta divulgación caracteriza entidades químicas (p.ej., un compuesto que presenta actividad como agente desacoplante mitocondrial o una sal y/o hidrato y/o cocristal farmacéuticamente aceptable de los mismos; p.ej., un compuesto, tal y como niclosamida o una sal y/o hidrato y/o cocristal farmacéuticamente aceptable de los mismos; p.ej., un compuesto, tal y como un análogo de niclosamida, o una sal y/o hidrato y/o cocristal farmacéuticamente aceptable de los mismos) las cuales son útiles, p.ej., para el tratamiento de uno o más síntomas de una patología que se caracteriza por una respuesta inflamatoria anormal (p.ej., trastorno inflamatorio del intestino) en un individuo (p.ej., un humano). También, esta divulgación caracteriza composiciones, además de otros métodos para utilizarlas y hacerlas
CR20180185A 2015-09-01 2016-09-01 Métodos y composiciones para el tratamiento de estados de enfermedad asociados con respuestas inflamatorias anormales CR20180185A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562213016P 2015-09-01 2015-09-01
US201562241508P 2015-10-14 2015-10-14
PCT/US2016/050012 WO2017040864A1 (en) 2015-09-01 2016-09-01 Methods and compositions for treating conditions associated with an abnormal inflammatory responses

Publications (1)

Publication Number Publication Date
CR20180185A true CR20180185A (es) 2018-12-06

Family

ID=58097295

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180185A CR20180185A (es) 2015-09-01 2016-09-01 Métodos y composiciones para el tratamiento de estados de enfermedad asociados con respuestas inflamatorias anormales

Country Status (21)

Country Link
US (11) US10292951B2 (es)
EP (1) EP3344274A4 (es)
JP (2) JP6955648B2 (es)
KR (1) KR20180080189A (es)
CN (1) CN109562137A (es)
AU (2) AU2016315852B2 (es)
BR (1) BR112018004069A2 (es)
CA (1) CA2997136A1 (es)
CL (1) CL2021000622A1 (es)
CO (1) CO2018003465A2 (es)
CR (1) CR20180185A (es)
EA (1) EA201890618A1 (es)
HK (1) HK1258048A1 (es)
IL (1) IL257801A (es)
MX (3) MX2018002586A (es)
PE (1) PE20181295A1 (es)
PH (1) PH12018500448A1 (es)
SG (1) SG10201914118SA (es)
TN (1) TN2018000069A1 (es)
UA (1) UA125747C2 (es)
WO (1) WO2017040864A1 (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
HRP20141094T1 (hr) 2008-07-08 2015-01-16 Incyte Corporation 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze
EP3061821B1 (en) 2009-07-22 2019-07-10 Puretech Health LLC Compositions for treatment of disorders ameliorated by muscarinic receptor activation
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
DK3010511T3 (en) 2014-09-12 2018-03-05 Antibiotx As ANTIBACTERIAL USE OF HALOGENERED SALICYLANILIDES
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
CN104880428B (zh) * 2015-06-23 2016-07-06 山西振东安特生物制药有限公司 一种胶体果胶铋或含胶体果胶铋制剂中铋含量的测定方法
PE20181295A1 (es) 2015-09-01 2018-08-07 First Wave Bio Inc Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala
WO2017079669A1 (en) * 2015-11-04 2017-05-11 Incyte Corporation Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
WO2018170254A1 (en) 2017-03-15 2018-09-20 Georgetown University Treating cancer with a cck receptor inhibitor and an immune checkpoint inhibitor
MX2019011287A (es) * 2017-03-21 2019-12-19 Novalead Pharma Inc Agente terapéutico para la inhibición de fosfodiesterasas y sus trastornos relacionados.
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
KR102459936B1 (ko) * 2017-10-13 2022-10-27 주식회사 엘지생활건강 알칸닌을 포함하는 구강질환 예방 또는 치료용 조성물
US10933061B2 (en) 2017-12-21 2021-03-02 Shepherd Therapeutics, Inc. Pyrvinium pamoate therapies and methods of use
EP3773579A4 (en) 2018-03-26 2022-03-09 Clear Creek Bio, Inc. COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
AU2019299217B2 (en) 2018-07-03 2025-04-03 Fennec Pharmaceuticals, Inc. Formulations of anhydrous sodium thiosulfate
IL261670B (en) * 2018-09-06 2019-06-30 Tudu Holdings Ltd A preparation that includes magnesium and its uses
CN109180600A (zh) * 2018-09-21 2019-01-11 五邑大学 一种麝香草酚类似物及其应用
EP3856182B1 (en) 2018-09-28 2025-12-24 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3639822A1 (en) * 2018-10-15 2020-04-22 Universität Regensburg Compound for use in the treatment of a disease characterized by dysregulated mucus production and/or secretion
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EP3873941A4 (en) * 2018-10-31 2022-07-27 Merck Sharp & Dohme Corp. ANTI-HUMAN PD-1 ANTIBODY CRYSTALS AND METHODS OF USE THEREOF
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
MX2021011491A (es) * 2019-03-22 2022-01-18 Mannkind Corp Polvos secos inhalables.
WO2020214960A1 (en) * 2019-04-18 2020-10-22 Prevep Llc Therapeutic combinations, liquid pharmaceutical compositions, kits for their preparation, and methods of their use
CN111032030B (zh) * 2019-04-28 2023-02-17 深圳市中医院 氯硝柳胺乙醇胺盐在制备治疗系统性红斑狼疮及其并发症的药物中的应用
CN112007036B (zh) * 2019-05-29 2022-01-21 百岳特生物科技（上海）有限公司 化合物及其组合物用于制备缓解肺上皮细胞发炎的医药品的用途
CN110200935B (zh) * 2019-06-03 2021-03-02 浙江得恩德制药股份有限公司 一种胶体果胶铋胶囊及其制备工艺
JP6622950B1 (ja) * 2019-07-08 2019-12-18 株式会社Moresco マイクロエマルションを調製するための組成物、マイクロエマルション、これらの製造方法、及びマイクロエマルションの利用
CN112341397B (zh) * 2019-08-09 2023-05-23 成都苑东生物制药股份有限公司 吡嗪类衍生物或盐、异构体、其制备方法及用途
PL3797771T3 (pl) * 2019-09-03 2022-06-27 Square Power Ltd Rebamipid do stosowania w zapobieganiu i leczeniu celiakii
US20210114973A1 (en) * 2019-10-18 2021-04-22 First Wave Bio, Inc. Pharmaceutical formulations
KR102300846B1 (ko) * 2019-11-01 2021-09-09 서울대학교산학협력단 면역 활성 개선용 조성물 및 이의 방법
CN111122523B (zh) * 2019-12-06 2021-09-28 山西大学 一种快速识别Ag+和Cys的三相输出功能的分子逻辑门及其构建方法
WO2021142240A1 (en) 2020-01-10 2021-07-15 First Wave Bio, Inc. Compositions comprising niclosamide for use in treating conditions associated with an abnormal inflammatory response
WO2021142238A1 (en) 2020-01-10 2021-07-15 First Wave Bio, Inc. Deuterated niclosamide
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
US20230190684A1 (en) 2020-03-16 2023-06-22 First Wave Bio, Inc. Methods of treating covid-19 with a niclosamide compound
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
IL296520A (en) * 2020-03-19 2022-11-01 Trizell Ltd Temperature-responsive virus storage system
US20210300873A1 (en) 2020-03-20 2021-09-30 Clear Creek Bio, Inc. Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
CN112914547A (zh) * 2020-03-22 2021-06-08 复旦大学附属华山医院 内源性神经干细胞磁共振无创性示踪技术体系及建立方法
JP2023520229A (ja) * 2020-04-01 2023-05-16 ユニオン・セラピューティクス・アー／エス 製剤
US11045434B1 (en) * 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease
EP4146172A1 (en) * 2020-05-05 2023-03-15 NeuroBo Pharmaceuticals, Inc. Niclosamide formulations and methods of use
CA3183146A1 (en) * 2020-05-13 2021-11-18 The Regents Of The University Of California Thiol-containing compounds for use in treating coronavirus
CN112057623A (zh) * 2020-06-03 2020-12-11 江苏靶标生物医药研究所有限公司 一种磷脂酰丝氨酸在制备治疗炎症性肠病药物中的应用
WO2021255218A1 (en) * 2020-06-19 2021-12-23 Charité - Universitätsmedizin Berlin A pharmaceutical combination comprising an anti-viral protonophore and a serine protease inhibitor
CN111650307A (zh) * 2020-07-13 2020-09-11 重庆医药高等专科学校 一种同时对酒中解热镇痛类药品非法添加物定性定量检测的方法及应用
WO2022020659A1 (en) * 2020-07-23 2022-01-27 Purdue Research Foundation Ohpp-formulated niclosamide to treat sars-cov-2, other viral diseases, and cancers
CA3191727A1 (en) * 2020-08-14 2022-02-17 Mayo Foundation For Medical Education And Research Methods and materials for tissue ablation
US20220080020A1 (en) * 2020-08-22 2022-03-17 Luc Montagnier Compositions and methods for reducing the transmissivity of illnesses using an oral delivery system
CN111920824A (zh) * 2020-09-11 2020-11-13 余朝权 一种治疗伤口的中药组合物
KR102636847B1 (ko) 2020-09-18 2024-02-19 경북대학교 산학협력단 티아민 유도체를 포함하는 이식편대숙주질환 예방 또는 치료용 약학적 조성물
CN114246852B (zh) * 2020-09-21 2024-08-16 暨南大学 一种药物组合物在心脑血管疾病中的应用
KR102378590B1 (ko) * 2020-09-28 2022-03-24 (주)위바이오트리 난용성 약물을 포함하는 금속 (수)산화물 복합체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
WO2022093871A1 (en) * 2020-10-26 2022-05-05 The Regents Of The University Of California Sars-c0v-2 inactivation by ethacridine
CN112342028B (zh) * 2020-10-28 2021-07-09 中铁建华南建设(广州)高科技产业有限公司 盾构分散剂及其制备方法和应用
WO2022091065A1 (ko) * 2020-11-02 2022-05-05 (주)아이엠디팜 신규한 공결정, 이를 포함하는 약학 조성물 및 이의 제조 방법
CN112526032B (zh) * 2020-12-28 2022-05-17 北京金城泰尔制药有限公司 聚甲酚磺醛的检测方法
WO2022147499A1 (en) * 2021-01-04 2022-07-07 Neurobo Pharmaceuticals, Inc. Method of treating viral infections with a combination of niclosamide and gemcabene
WO2022159326A1 (en) 2021-01-19 2022-07-28 Erimos Pharmaceuticals, Llc Terameprocol and nordihydroguaiaretic acid (ndga) derivatives as coronavirus anti-viral agents
JP7733935B2 (ja) * 2021-01-28 2025-09-04 イムドファーム インコーポレイテッド カモスタット及びニクロサミドを含む共結晶、それを含む薬学組成物、及び、その製造方法
CN112826795B (zh) * 2021-03-23 2022-08-30 重庆医科大学 一种载汉防己甲素脂质体制剂及其制备方法和应用
WO2022204397A1 (en) * 2021-03-26 2022-09-29 First Wave Biopharma Treatment of long haulers syndrome with niclosamide
CN113368064B (zh) * 2021-06-08 2022-06-28 吉林津升制药有限公司 一种烟酸冻干粉及其制备方法
CN114134195B (zh) * 2021-11-03 2024-06-11 南方科技大学 预防前列腺癌的药剂的筛选方法、硝唑尼特在制药中的应用
US20230203604A1 (en) * 2021-11-23 2023-06-29 nference, inc. Detection of covid-19 associated cardiac injury and vaccine-associated myocarditis
CN113908154A (zh) * 2021-11-29 2022-01-11 中国药科大学 硝唑尼特及其体内代谢物替唑尼特在抗银屑病及银屑病样皮肤炎症中的应用
CN114393662A (zh) * 2021-12-21 2022-04-26 凭祥青山中密度纤维板有限公司 一种环保中密度纤维板的制备方法
JP2025518339A (ja) * 2022-01-31 2025-06-12 リビオネックス・インコーポレイテッド 鉄キレート化のための新規液体製剤
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
CN114796135B (zh) * 2022-03-29 2023-04-07 海南久常制药有限公司 一种硫糖铝口服制剂及其制备方法
CN114652734A (zh) * 2022-03-31 2022-06-24 李红梦 一种祛痘的药物组合物及其制备方法
CN114767871B (zh) * 2022-04-19 2023-04-07 中国工程物理研究院机械制造工艺研究所 介孔硅载药体系及制备方法和介孔硅载药
CN117045657A (zh) * 2022-05-12 2023-11-14 广州嘉越医药科技有限公司 一种药物组合及其应用
WO2024029639A1 (ko) * 2022-08-02 2024-02-08 제이투에이치바이오텍 주식회사 3성분 프로드럭, 이의 약학적 조성물 및 의약 용도
CN115494231A (zh) * 2022-09-02 2022-12-20 武汉三鹰生物技术有限公司 一种蛋白酶抑制剂混合物及其制备方法与应用
CN115739028B (zh) * 2022-11-26 2024-04-02 西南政法大学 一种精神活性物质吸附剂及其应用
CN116036289B (zh) * 2023-02-03 2025-05-06 中国药科大学 一种增强铁死亡治疗效果的纳米制剂及其制备方法和应用
CN116077424B (zh) * 2023-02-17 2025-06-03 重庆大学 一种多功能仿生水凝胶及其制备方法和应用
WO2024182078A1 (en) * 2023-02-28 2024-09-06 Verté Therapeutics, Llc Veterinary transdermal gel comprising ondansetron, and related methods
CN116139116A (zh) * 2023-03-30 2023-05-23 中南大学湘雅医院 氯硝柳胺在抑制急性肝衰竭中的应用
CN116531366B (zh) * 2023-05-23 2025-02-14 新乡医学院 罗替戈汀的药物新用途
WO2025037323A1 (en) * 2023-08-12 2025-02-20 Pavan Kumar Kothapuvari Pharmaceutical compositions for treatment of dry eye disease and associated disorders
CN117883443A (zh) * 2023-12-12 2024-04-16 中国海洋大学 吡罗克酮乙醇胺盐在制备治疗胃肠道疾病的药物中的应用
CN117899225A (zh) * 2024-01-19 2024-04-19 芮城绿曼生物药业有限公司 一种增强免疫力的兽用抗菌注射剂、制备方法及应用
WO2025216845A1 (en) * 2024-04-12 2025-10-16 Advancion Corporation Paint and coating formulations including 3-amino-2-butanol and uses thereof
CN119055625B (zh) * 2024-07-23 2025-09-09 湖北工业大学 Tiratricol在制备抗ADV7病毒药物中的应用
CN120204184A (zh) * 2025-02-17 2025-06-27 深圳市第三人民医院(深圳市肝病研究所) 阿米替林和/或其衍生物的应用、结核分枝杆菌抑制剂和药物组合物
CN119700664B (zh) * 2025-02-28 2025-06-20 山东新时代药业有限公司 含有活性成分琥珀酸普芦卡必利的注射液及其制备方法
CN120713881B (zh) * 2025-08-21 2025-12-05 南方科技大学 氯硝柳胺在治疗器官移植排斥反应中的应用

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3079297A (en) 1960-05-31 1963-02-26 Bayer Ag Method of combating gastropods
US3927195A (en) * 1974-01-31 1975-12-16 Lilly Industries Ltd Production of capsules
FR2505798B1 (fr) 1981-05-14 1986-07-25 Pari Symac Perfectionnement aux dispositifs comportant un ressort helicoidal utilise comme organe de transfert, d'extraction, de dosage ou de melange
NZ223200A (en) 1988-01-15 1989-01-06 Ancare Distributors Anthelmintic compositions containing 2',5-dicloro-4'-nitrosalicylanilide and non aqueous carrier
DE4005528C2 (de) 1990-02-22 1998-01-15 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
US5280784A (en) 1990-09-19 1994-01-25 Paul Ritzau Pari-Werk Gmbh Device in particular and inhalating device for treating the lung and the respiratory tracts
DE59107894D1 (de) 1991-03-21 1996-07-11 Ritzau Pari Werk Gmbh Paul Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie
DK0540775T3 (da) 1991-11-07 1997-08-25 Ritzau Pari Werk Gmbh Paul Forstøver især til anvendelse i apparater til inhalationsterapi
ATE121971T1 (de) 1991-11-07 1995-05-15 Ritzau Pari Werk Gmbh Paul Flüssigkeitszerstäubervorrichtung.
DE4225928A1 (de) 1992-08-05 1994-02-10 Ritzau Pari Werk Gmbh Paul Zerstäubervorrichtung mit Heizeinrichtung
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DE4310575C1 (de) 1993-03-31 1994-09-15 Ritzau Pari Werk Gmbh Paul Vorrichtung zum Erzeugen von Aerosolpulsen
ES2120471T3 (es) 1993-12-17 1998-11-01 Pari Gmbh Spezialisten Fuer Effektive Inhalation Boquilla de pulverizacion.
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US6000394A (en) 1994-10-26 1999-12-14 Paul Rizau Pari-Werk Gmbh Generation of an aerosol of an exact dose
US5663155A (en) * 1994-11-30 1997-09-02 The University Hospital Compositions for the treatment of parasitic infections
DE19520622C2 (de) 1995-06-06 2003-05-15 Pari Gmbh Vorrichtung zum Vernebeln von Fluiden
DE19602628C2 (de) 1996-01-25 2000-06-29 Pari Gmbh Vernebler
EP0821970A1 (en) 1996-08-02 1998-02-04 Edward Henri Charles Verhaeren Carrier composition for influencing the tight junction permeability
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
DE19734022C2 (de) 1997-08-06 2000-06-21 Pari Gmbh Inhalationstherapiegerät mit einem Ventil zur Begrenzung des Inspirationsflusses
US5905090A (en) 1998-04-29 1999-05-18 Italfarmaco S.P.A. Analogues of the active metabolite of leflunomide
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
DE19827228C2 (de) 1998-06-18 2000-07-13 Pari Gmbh Flüssigkeitszerstäubervorrichtung
US7635722B1 (en) 1998-07-27 2009-12-22 Saint Jude Pharmaceuticals, Inc. Chemical induced intracellular hyperthermia
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
DE19962110C2 (de) 1999-12-22 2003-06-12 Pari Gmbh Inhalationsvernebler mit einstückigem Ventilelement
AU2001260083A1 (en) * 2000-05-26 2001-12-03 Dr. Reddy's Research Foundation New pharmaceutical composition and the process for its preparation
EP1844766B1 (en) 2000-12-18 2012-04-18 Institute of Medicinal Molecular Design, Inc. Inhibitors against the production and release of inflammatory cytokines
US7132546B2 (en) 2000-12-22 2006-11-07 Ishihara Sangyo Kaisha, Ltd. Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
JP2004517699A (ja) 2001-01-30 2004-06-17 ボード オブ リージェンツ ユニバーシティ オブ テキサス システム 液体中への噴霧凍結によるナノ粒子およびミクロ粒子の製造方法
US20040022861A1 (en) 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
US20040071757A1 (en) 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
AU2003249244A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
JP4933732B2 (ja) 2003-01-15 2012-05-16 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 低温表面上で凍結させることによって得られる薬物粒子
TWI343810B (en) 2003-05-28 2011-06-21 Nat Health Research Institutes A pharmaceutical composition for inhibiting coronavirus
US20050123571A1 (en) * 2003-06-06 2005-06-09 Rossini Aldo A. Modulation of apoptosis
US7249224B2 (en) 2003-08-05 2007-07-24 Newisys, Inc. Methods and apparatus for providing early responses from a remote data cache
DE10340277B4 (de) 2003-08-29 2006-11-23 Bio-Gate Bioinnovative Materials Gmbh Körperpflegemittel mit Silber-Agglomeraten
EP1774028A4 (en) 2004-07-07 2008-05-07 Dana Farber Cancer Inst Inc METHOD AND COMPOSITIONS FOR TREATING OBESITY
CN1626506A (zh) 2004-08-10 2005-06-15 李志良 高纯度、高收率氯硝柳胺的制备
JP2008511637A (ja) 2004-08-27 2008-04-17 ザ ダウ ケミカル カンパニー 致命的な感染症を治療する薬剤組成物の増強された供給
US20100041657A1 (en) 2005-05-11 2010-02-18 Novo Nordick A/S Haloalkylsulfone substituted compounds useful for treating obesity and diabetes
JP2008545677A (ja) 2005-05-23 2008-12-18 ノボ ノルディスク アクティーゼルスカブ 新規なハロアルコキシ置換サリチル酸アニリド
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
WO2008021088A2 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
EP2124898B1 (en) 2007-01-10 2013-08-14 Board of Regents, The University of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
DK2170283T3 (en) 2007-06-22 2019-04-15 Univ Texas CREATION OF STABLE SUBMICRON Peptide OR PROTEIN PARTICLES BY THIN FILM FREEZING
US8262657B2 (en) 2007-08-16 2012-09-11 Nutek Orthopaedics, Inc. External fixation apparatus with adjustable pin clamping means and convergent bone pins
KR101500792B1 (ko) 2008-01-10 2015-03-09 에보니크 룀 게엠베하 결장에서 증가된 활성 물질 방출을 갖는 코팅된 제약학적 또는 건강기능성 제제
CA2723314C (en) 2008-02-13 2017-01-10 The Board Of Regents, The University Of Texas System Templated open flocs of anisotropic particles for enhanced pulmonary delivery
EP2123626A1 (en) 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
US20100215782A1 (en) 2008-10-22 2010-08-26 Metaproteomics, Llc Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis
CU23701A1 (es) 2008-12-29 2011-09-21 Ct Ingenieria Genetica Biotech Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i
MX341877B (es) 2009-06-26 2016-09-06 Romark Laboratories L C * Compuestos y métodos para tratar influenza.
CN101601670B (zh) 2009-06-30 2014-06-04 青岛蔚蓝生物股份有限公司 一种宠物用复方氯硝柳胺驱虫片剂及其制备方法
KR100990110B1 (ko) 2009-08-18 2010-10-29 엘지전자 주식회사 태양 전지
CN102834116B (zh) 2009-09-21 2015-09-16 杜克大学 Wnt/卷曲蛋白相关疾病的治疗
US9206394B2 (en) * 2010-02-03 2015-12-08 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
GB201015079D0 (en) 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
WO2012068274A1 (en) 2010-11-16 2012-05-24 University Of Medicine And Dentistry Of New Jersey Treatment of type ii diabetes and diabets-associated diseases with safe chemical mitochondrial uncouplers
US20140294957A1 (en) 2011-04-18 2014-10-02 Maxdelbruck-Centrum Fur Molekulare Medizin Niclosamide for the treatment of cancer metastasis
WO2012154944A2 (en) 2011-05-10 2012-11-15 Stc.Unm Methods of treating autophagy-associated disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits
CA2841358A1 (en) * 2011-07-15 2013-01-24 S.L.A. Pharma Ag Pharmaceutical compositions for rectal administration
CN109512805B (zh) 2012-05-08 2021-12-31 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
WO2014023329A1 (en) 2012-08-06 2014-02-13 Life And Brain Gmbh Niclosamide and its derivatives for use in the treatment of solid tumors
CN102861014A (zh) * 2012-10-16 2013-01-09 天津必佳药业集团有限公司 一种畜禽用抗蠕虫病复方氯硝柳胺片及其制备方法
CN103891720B (zh) * 2012-12-27 2016-02-17 陕西汤普森生物科技有限公司 一种含有螺枯威的复配杀螺组合物
CA3159085A1 (en) 2013-01-14 2014-07-17 Clinics Operations Limited Combination cancer therapeutics and uses thereof
WO2014138881A1 (en) * 2013-03-12 2014-09-18 Patheon, Inc. Drug delivery system
BR112015026283B1 (pt) 2013-04-23 2023-04-25 Société des Produits Nestlé S.A. Composição multiparticulada, método para fabricação da mesma e uso de uma pluralidade de núcleos com revestimentos entéricos individuais contendo um ou mais ingredientes ativos com base em terpeno
WO2014185973A2 (en) 2013-05-14 2014-11-20 The University Of Chicago Modulation of reactivation of a latent virus
WO2014200705A1 (en) * 2013-06-14 2014-12-18 Stc.Unm Treatment of autophagy-related disorders
JP6516740B2 (ja) * 2013-08-02 2019-05-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 幹細胞及びキメラ抗原受容体を介した抗腫瘍性ｔ細胞免疫の改変
CN105899223A (zh) 2013-10-28 2016-08-24 加利福尼亚大学董事会 转移性前列腺癌的治疗
EP4491180A1 (en) 2014-01-10 2025-01-15 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CN103751854B (zh) 2014-01-20 2015-08-26 瞿介明 抗菌医用导管
ES2731876T3 (es) 2014-10-23 2019-11-19 Singh Molecular Medicine Llc Anticuerpos de dominio sencillo contra antígenos intracelulares
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
JP6047203B2 (ja) 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬
US9566399B1 (en) 2015-04-14 2017-02-14 Clempharma LLC Deep lung alveolar aerosol targeted drug delivery
US20180147161A1 (en) 2015-05-01 2018-05-31 Board Of Regents, The University Of Texas System Multidrug brittle matrix compositions
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
CN105063018A (zh) * 2015-08-31 2015-11-18 山西大学 一种从葡萄成熟果实中提取总rna的方法
PE20181295A1 (es) 2015-09-01 2018-08-07 First Wave Bio Inc Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala
EP3168211A1 (en) 2015-11-10 2017-05-17 Westfälische Wilhelms-Universität Münster Pharmaceutical co-crystals of niclosamide
US10189797B2 (en) 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use
US10588864B2 (en) 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery
WO2017223491A1 (en) 2016-06-23 2017-12-28 Health Research, Inc. Pharmaceutical compositions with antiflaviviral activity
BR112019000796A2 (pt) 2016-07-16 2019-04-24 Florida State University Research Foundation, Inc. compostos e métodos para tratamento e prevenção da infecção flavivirus
KR101928543B1 (ko) 2017-01-09 2018-12-13 사단법인 분자설계연구소 니클로사마이드를 함유하는 Axin-GSK3 단백질 결합 관련 질환 치료용 약학조성물
US20210052621A1 (en) 2017-01-17 2021-02-25 The Regents Of The University Of California Methods for treating flaviviruses and zika infections
US10940163B2 (en) 2017-02-02 2021-03-09 Mcmaster University Bicarbonate as a potentiator for antimicrobial agents
MX2019011287A (es) 2017-03-21 2019-12-19 Novalead Pharma Inc Agente terapéutico para la inhibición de fosfodiesterasas y sus trastornos relacionados.
WO2018191776A1 (en) 2017-04-18 2018-10-25 Inspiring Pty Ltd Dry powder inhaler and spacer device for a dry powder inhaler
WO2018205016A1 (en) 2017-05-08 2018-11-15 The Governors Of The University Of Alberta Peroxisome biomarkers in hiv disease progression and peroxisome activating drugs for hiv treatment
US11529476B2 (en) 2017-05-19 2022-12-20 Pneuma Respiratory, Inc. Dry powder delivery device and methods of use
WO2019051440A1 (en) 2017-09-11 2019-03-14 Board Of Regents, The University Of Texas System MEDICAMENT COMPOSITIONS COMPRISING POROUS MEDIA PRODUCED BY THERMAL OR FUSION-BASED METHODS
US20200206139A1 (en) 2017-09-11 2020-07-02 Board Of Regents, The University Of Texas System Compositions for the improved delivery of drugs
CA3085943A1 (en) 2017-12-21 2019-06-27 Civitas Therapeutics, Inc. Surfactant formulations for inhalation
WO2019147626A1 (en) 2018-01-23 2019-08-01 The Trustees Of Columbia University In The City Of New York Activation of mitochondrial uncoupling as a therapeutic intervention
WO2019217164A1 (en) 2018-05-09 2019-11-14 Reyoung Corporation Compositions and methods for treating cancer and other diseases
US11166926B2 (en) 2018-08-08 2021-11-09 The Hospital For Sick Children Compositions and methods for protecting a host from enteric toxigenic pathogens
EP4019002A4 (en) 2019-08-23 2023-03-01 Daewoong Pharmaceutical Co., Ltd NICLOSAMIDE DELAYED RELEASE COMPOSITION AND ITS ANTIVIRAL USE
US20210114973A1 (en) 2019-10-18 2021-04-22 First Wave Bio, Inc. Pharmaceutical formulations
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US11045434B1 (en) 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease

Also Published As

Publication number Publication date
IL257801A (en) 2018-04-30
CO2018003465A2 (es) 2018-08-31
US10744103B2 (en) 2020-08-18
US11793777B2 (en) 2023-10-24
US20200147012A1 (en) 2020-05-14
MX2023014409A (es) 2023-12-13
EP3344274A1 (en) 2018-07-11
EA201890618A1 (ru) 2018-10-31
MX2022014310A (es) 2022-12-07
BR112018004069A2 (pt) 2021-07-13
US10799468B2 (en) 2020-10-13
US10292951B2 (en) 2019-05-21
PH12018500448A1 (en) 2018-09-24
EP3344274A4 (en) 2019-05-22
US20210401784A1 (en) 2021-12-30
TN2018000069A1 (en) 2019-07-08
US20240074995A1 (en) 2024-03-07
US20170056347A1 (en) 2017-03-02
US10912746B2 (en) 2021-02-09
US10905666B2 (en) 2021-02-02
CL2021000622A1 (es) 2021-10-01
AU2016315852B2 (en) 2023-06-15
CN109562137A (zh) 2019-04-02
AU2016315852A1 (en) 2018-03-22
JP7189983B2 (ja) 2022-12-14
US20200197339A1 (en) 2020-06-25
US10772854B2 (en) 2020-09-15
JP2018529762A (ja) 2018-10-11
US20200276140A1 (en) 2020-09-03
WO2017040864A1 (en) 2017-03-09
JP2021098727A (ja) 2021-07-01
KR20180080189A (ko) 2018-07-11
HK1258048A1 (zh) 2019-11-01
JP6955648B2 (ja) 2021-10-27
SG10201914118SA (en) 2020-02-27
US20190298670A1 (en) 2019-10-03
US20200197340A1 (en) 2020-06-25
US20200268694A1 (en) 2020-08-27
PE20181295A1 (es) 2018-08-07
AU2023203354A1 (en) 2023-07-06
US20220000812A1 (en) 2022-01-06
US10849867B2 (en) 2020-12-01
UA125747C2 (uk) 2022-06-01
US20200147013A1 (en) 2020-05-14
CA2997136A1 (en) 2017-03-09
MX2018002586A (es) 2020-11-24

Similar Documents

Publication Publication Date Title
CR20180185A (es) Métodos y composiciones para el tratamiento de estados de enfermedad asociados con respuestas inflamatorias anormales
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
NI201600164A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CU20170077A7 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos, composiciones y combinaciones que lo comprende
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
MX2021009673A (es) Moduladores de ror-gamma.
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
MX2017015521A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
MX375706B (es) Compuestos de inhibidor de autotaxina.
MX381640B (es) Metodos y compuestos agonistas de gip.
CL2013002446A1 (es) Compuestos derivados de quinolin-triazolopiridin-etilpirrolidina, como inihibidores de cinasa pim; proceso para su preparacion; compuestos intermediarios; composicion que los comprende, util para el tratamiento de una enfermedad inflamatoria o autoinmunitaria tal como esclerosis multiple y lupus, y para el tratamiento del cancer.
UY35971A (es) Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
GT201600123A (es) Inhibidores de syk
MX2017011269A (es) Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
UY36215A (es) Espirocicloheptanos como inhibidores de rock
BR112016023815A2 (pt) composições tópicas para o alívio da dor, produção e uso
ECSP17046848A (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y osteoartritis
MX392523B (es) Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar
CR20160433A (es) Nuevos compuestos
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CU20200038A7 (es) Compuestos derivados de pirazolo-pirrolo-pirimidina-diona como inhibidores de p2x3
CU20160139A7 (es) Benzamidas y anilidas sustituidas en calidad de inhibidores de las vías de de señalización wnt, las composiciones y combinaciones farmacéuticas que las comprenden, y los compuestos intermediarios útiles para preparar estos compuestos
MX2017008373A (es) Compuestos, composiciones y metodos.
CL2018000559A1 (es) Métodos y composiciones para tratar condiciones asociadas con respuestas inflamatorias anormales
NI201500172A (es) Composiciones farmacéuticas